To determine the effects of EE/CA (Ethinylestradiol/ Cyproterone Acetate) and EE/CA-metformin treatments on the asymmetric dimethylarginine (ADMA) levels in women with PCOS (Polycystic Ovary Syndrome). Among 43 patients diagnosed with PCOS, one study arm (n=22) was administered (35 μg EE, 2mg CA) and the other (n=21) was administered (35 μg EE, 2mg CA plus 1700mg metformin). Serum ADMA, lipid profile, androgens, insulin, and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance ) values were assessed prior to treatment and after 3 months of therapy. A significant reduction in ADMA levels relative to pre-treatment in the EE/ CA+metformin group (1.2±0.4 vs 0.95±0.4, p=0.016) compared to the EE/CA group (1.0±0.5 vs 1.03±0.4, p >0.05). Andogens, insulin and HOMA-IR levels decreased in both treatment groups. All lipid profiles significantly improved in-group EE/ CA+metformin while no significant decrease was observed in TG and HDL-cholesterol levels in EE/CA group. Post-treatment levels of HDL-C levels correlated significantly with the reducing ADMA levels in the EE/CA+metformin group (P=0.005, r= 0.602). Adding metformin to EE/ CA therapy in PCOS may beneficial endothelium effects associated with reduction of ADMA levels.
Introduction
Women with PCOS (Polycystic Ovary Syndrome) have multiple risk factors for the development of cardiovascular disease, including hyperandrogenemia, insulin resistance, glucose intolerance, obesity and endothelial dysfunction [1] . It has recently been demonstrated that patients with PCOS frequently exhibit elevated ADMA levels relative to normal subjects [2] [3] [4] [5] . ADMA (asymmetric dimethylarginine) is an endogenous inhibitor of endothelial nitric oxide synthase (NOS) through competition with L-arginine [6] , which is thought to be key factor contributing to endothelial dysfunction [6] . Lowering of ADMA levels may possibly have important therapeutic effects. More recently, ADMA levels were found to be decreased after EE/CA (Ethinylestradiol/ Cyproterone Acetate) [3, 4] and metformin [2, 4] treatments in women with PCOS.
In women with PCOS, according to recent reports, the oral contraceptive pill (OCP) is more effective than insulin-sensitizing drugs in improving menstrual pattern and reducing serum androgen levels [7] . Metformin, Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome an insulin-sensitizing drug (ISD), is not as effective as OCP in reducing androgens but more effective than the OCP in reducing fasting insulin levels and meanwhile controlling triglyceride levels [8, 9] . Nevertheless, at an accelerating pace data support the preferential use of insulin-sensitising drugs in combination OCP for the medical management of PCOS patients [10, 11] . To our best knowledge there is no data regarding EE/CA plus metformin treatment on ADMA levels in PCOS patients. The relationship between PCOS and variation in serum ADMA levels under EE/CA and EE/CA plus metformin treatments are still a potential research area. The aim of the study was to investigate EE/CA alone and EE/CA combined with metformin treatments on serum ADMA levels in women with PCOS.
Material and Methods
Forty-three PCOS patients, who were diagnosed according to the criteria of the Rotterdam European Society of Human Reproduction and EmbryologyAmerican Society for Reproductive Medicine-sponsored PCOS consensus workshop group, were included in the study [12] . All eligible patients presented with at least two of the three following criteria: [1] oligomenorrhea or amenorrhea, [2] clinical (hirsutism, acne) and/ or biochemical signs of hyperandrogenism, and [3] polycystic ovaries. The local ethical committee approved the study and informed consent was obtained from all subjects. All women had normal thyroid, renal and hepatic functions. None of them had late-onset congenital adrenal hyperplasia. Women who had any medication (e.g., antihypertensives, oral antidiabetics, oral contraceptives, antiandrogens, statins, vitamins, warfarin, antidepressant medication, and GnRH agonists and antagonists) in the preceding 3 months were not included to the study. Women with hypertension, diabetes, history of coronary heart disease, known coagulation abnormalities and current smokers and cronic alcohol users were also not included. All patients were normal (<100 mg/dL) fasting glucose levels. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters.
Patients were randomly assigned to one of two treatment groups. Patients in group A (n=22) received 35 µg EE + 2mg CA; (Diane Nova, Shering, Germany); 21 days per month followed by a 7-day pill-free period). Patients in group B (n=21) received metformin 850 mg twice a day) (Glucophage, Merck Lipha lab, Lyon, France) and 35 µg EE + 2mg CA; for 3 months. All the patients were closely followed up during the study period. No subjects were lost during the follow up and none of the 43 patients had stopped the therapies because of adverse effects. All blood samples were obtained in the morning between 08:00 and 09:00 h after an overnight fast during the early follicular phase (day 2-5) of a spontaneous or progesterone induced menstrual cycle in PCOS women. Measurements were taken on recruitment and repeated after 3 months of treatment. The samples were centrifuged, aliquoted and immediately frozen at −80
• C until the analyses of serum ADMA, lipoproteins and hormones.
Laboratory Tests
Serum glucose, total cholesterol (TC), triglyceride (TG) and HDL-cholesterol (HDL-C) levels were measured using Randox enzymatic kits in Roche-Hitachi Modular system. LDL-cholesterol (LDL-C) was calculated by the Friedewald equation method. The serum concentration of DHEA-S was measured by chemiluminescent enzyme immunoassay (Immulite 2000 Diagnostic Products Corporation LA, CA, USA). Serum free T (FT) levels were measured by a RIA method (Diagnostic Systems Laboratories, Webster, TX, USA). Fasting insulin levels were determined by a chemiluminescent method (Roche Diagnostics, Mannheim, Germany) utilizing an automatic immunoanalyzer. An insulin resistance score Homeostasis Model Assessment-Insulin resistance (HOMA-IR) was computed by the following formula: HOMA-IR = fasting serum glucose (mg/dL) x fasting insulin (µIU/mL) / 405.
Measurement of serum ADMA levels
Serum ADMA levels were measured by competitive ELISA (DLD Diagnostika GmbH, Germany) with detection limit of 0.05µmol/L. As described previously, intra-assay coefficients of variation were 7.5% at 0.81µmol/L and 4.5% at 1.76 µmol/L, and interassay coefficients of variation ranged from 8.3% to 10.3% [13, 14] .
Statistical analysis
Results are expressed as mean ± SD. P values less than 0.05 were considered significant. Because variables were not distributed normally as checked by Kolmogorov-Smirnoff test, nonparametric testing for further analysis was used. The differences between the PCOS subgroup of women treated with either EE/CA or EE/CA combined metformin were assessed using the Mann-Whitney-U test. Within-group differences (EE/ CA or EE/CA combined metformin) were analyzed with the Wilcoxon test. Relations between variables were investigated using Spearman's bivariate correlation in PCOS women. All statistical analyses were done using Statistical Package for Social Sciences version 12.0 (SPSS Inc., Chicago, IL, USA).
Results
Forty three patients [mean age, 24.6±5.0yr; mean body mass index (BMI), 27.9 ± 5.4 kg/m 2 ] successfully completed the study. Antropometric and clinical characteristics of the patients before and after the treatments are reported in Table 1 and 2.
In the EE/CA treated group, pre-and post-treatment clinical and laboratory characteristics and the results of comparisons are shown in Table 2 . BMI, HOMA-IR, insulin, TC, LDL-C, DHEA-S and FT decreased significantly after the EE/CA treatment (p<0.05). TG and HDL-C did not differ significantly after the EE/CA therapy. Serum levels of ADMA concentration did not significantly change after the EE/CA treatment (Table 2, P >0.05).
In the EE/CA combined metformin treated group, preand post-treatment clinical and laboratory characteristics and the results of comparisons are given in Table 2 . The levels of BMI, insulin, HOMA-IR, TC, LDL-C, TG, DHEA-S, and FT decreased whereas HDL-C increased significantly after the EE/CA-metformin treatment (p<0.05). Serum levels of ADMA levels decreased (P = 0.016) after the EE/CA-metformin treatment. In the combined group of PCOS women post-treatment levels of HDL-C correlated significantly with the reducing ADMA levels (Figure 1, P=0 .005, r= 0.602).
Discussion
We have monitored serum lipid profile, insulin sensitivity, androgens, ADMA levels in two groups of PCOS patients randomly submitted to treatment with OCP's, which regularized TC, LDL-C, HOMA-IR, insulin, androgens in cases whereas did not change ADMA levels. Adding metformin to treatment, improved all lipid profiles, HOMA-IR, insulin, androgens and also ADMA levels after 3 months of therapy.
Decreasing ADMA was only seen in combinations of EE/CA-metformin not in alone EE/CA in our study. In more recent reports, contrary to our findings, Ozgurtas Table 2 . Comparisons of pre-and post-treatment clinical and laboratory characteristics in treatment groups (mean±SD) (P* Before vs after therapy for EE/CA group; P** Before vs after therapy for EE/CA plus metformin group ).
Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome significantly decreased after treatment in women with PCOS. This may be due to the HDL-cholesterol levels. HDL-C level which was unaffected by EE/CA in our study whereas it increased significantly in Ozgurtas report. Several recent studies have demonstrated that HDL-C can stimulate production of nitric oxide (NO), which may contribute to the positive cardiovascular effects of HDL-C [15] . In this context, it has been recently suggested that HDL-C delivers estrogen to eNOS, thereby stimulating the enzyme, with the resultant generation of NO [16] . According to this view, in EE/CA group which pre-post treatment unchanged HDL-C levels did not alter ADMA levels in our study.
Moreover, progestins have been reported to impair the cardioprotective effects of estrogen, as well as decrease serum NO levels and increase of plasma NO metabolites; nitrate and nitrite, even in the presence of high concentrations of 17b-estradiol [17] . Estrogen increases HDL-C whereas progestins can induce HDL-C levels fall in association with an increase in hepatic lipase activity. This observations links progestin administration to antiestrogenic effects on nitric oxide synthesis. This shows the proatherosclerotic effects of progestin in the presence of estrogen [18] [19] [20] .
In recent years, there are two studies evaluating the importance of ADMA levels after metformin treatment in the specific population of PCOS [2] [3] [4] . Heutling D et al.
[2] randomized 21 patients with PCOS to receive metformin for 6 months. After the treatment period, metformin decreased ADMA levels, which was possibly independent of BMI and metabolic changes. Moreover, metformin had been shown to decrease circulating ADMA, both as monotherapy and as add-on therapy to sulphonylurea in poorly controlled type 2 diabetic patients [21] . In our study, the potential benefits of insulin-sensitizing drugs in combination OCP treatment was also be evaluated among those PCOS patients. Our findings were also in line previous studies that reported beneficial effect of metformin on ADMA levels. As an interesting finding of our study, decreased in serum ADMA level of the PCOS patients was found to be independent of such as insulin resistance and androgen levels in EE/CA-metformin group. Post-treatment in the combined group of PCOS women, the levels of HDL-C levels correlated only significantly with the reduction of ADMA levels. Hence, we may speculate that metformin may beneficial effects on risk factors for atherosclerosis by reducing ADMA levels in PCOS patients.
In our study, relatively small number of patients studied and shorter duration of follow-up, these may be considered as a limitation. However, previous studies claimed that 3-month treatment was sufficient for determining the drug-related effects especially in ADMA, hormonal and metabolic variables [4, 22, 23] In conclusion, we observed improvement of hormonal, and metabolical variables in both treatment groups. Among the treatment groups, EE/CA-metformin may be more effective therapeutic option than EE/CA protocol and this may be due to the beneficial effect of EE/CAmetformin on ADMA levels. 
